Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
Metrics: PDF 1671 views | HTML 2804 views | ?
Surajit Pathak1, Sushmitha S1, Antara Banerjee1, Francesco Marotta2, Madhumala Gopinath1, Ramachandran Murugesan1, Hong Zhang3, Bhavani B1, Agnishwar Girigoswami1, Jose Sollano4 and Xiao-Feng Sun5
1Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
2ReGenera Research Group for Aging-Intervention, Milano, Italy and San Babila Clinic, Healthy Aging Unit by Genomics and Biotechnology, Milano, Italy
3School of Medicine, Orebro University, Örebro, Sweden
4Gastroenterology Department, University of Santo Tomas, Manila, The Philippines
5Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
Xiao-Feng Sun, email: [email protected]
Surajit Pathak, email: [email protected]
Keywords: colorectal cancer; KRAS; bevacizumab; panitumumab; cetuximab
Received: October 15, 2016 Accepted: October 11, 2017 Published: November 16, 2017
Colorectal cancer, fourth leading form of cancer worldwide and is increasing in alarming rate in the developing countries. Treating colorectal cancer has become a big challenge worldwide and several antibody therapies such as bevacizumab, panitumumab and cetuximab are being used with limited success. Moreover, mutation in KRAS gene which is linked with the colorectal cancer initiation and progression further interferes with the antibody therapies. Considering median progression free survival and overall survival in account, this review focuses to identify the most efficient antibody therapy in combination with chemotherapy (FOLFOX-4) in KRAS mutated colorectal cancer patients. The bevacizumab plus FOLFOX-4 therapy shows about 9.3 months and 8.7 months of progression free survival for KRAS wild and mutant type, respectively. The overall survival is about 34.8 months for wild type whereas for the mutant it is inconclusive for the same therapy. In comparison, panitumumab results in better progression-free survival which is about (9.6 months) and overall survival is about (23.9 months) for the wild type KRAS and the overall survival is about 15.5 months for the mutant KRAS. Cetuximab plus FOLFOX-4 therapy shows about 7.7 months and 5.5 months of progression-free survival for wild type KRAS and mutant type, respectively. Thus, panitumumab shows significant improvement in overall survival rate for wild type KRAS, validating as a cost effective therapeutic for colorectal cancer therapy. This review depicts that panitumumab along with FOLFOX-4 has a higher response in colorectal cancer patients than the either of the two monoclonal antibodies plus FOLFOX-4.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.